Introduction
Venous thromboembolic disease (VTE) is a rare disease in childhood. The reported annual incidence ranges from 0.07 to 0.14 per 10,000 children and is estimated to be 5.3 per 10,000 hospital admissions.(1-3)The incidence seems to be increasing over the past decades. Raffini et al reported a rise in the annual incidence of VTE of 70%, from 34 to 58 cases per 10,000 hospital admissions.(4) This is confirmed by Boulet et al. (5) This rise is likely caused by an increased awareness of the disease, progress in radiologic imaging and increased survival of children with previously incurable diseases due to medical and surgical improvements.
In 2008 a systematic review and meta-analysis concerning pediatric VTE and inherited thrombophilia, i.e. deficiencies of antithrombin (AT), protein C (PC) and protein S (PS), and factor V Leiden mutation (FVL) and the prothrombin mutation (PTM), showed elevated thrombotic risks in children with these defects. (6) In the current review, we discuss additional literature after 2008 in various pediatric patient groups and the usefulness of thrombophilia testing.
Methods

In-and exclusion criteria
All full-text published studies of VTE and thrombophilia in neonates and children (0-18 years) from 2008 through October 2014 were evaluated for inclusion if 1) diagnosis of VTE of any location was objectively confirmed by accepted imaging methods, 2) frequency of at least one of the inherited thrombophilic factors was assessed in a given VTE cohort or if the frequency of inherited thrombophilic factors was compared between VTE patients and controls without a history of VTE, and 3) inherited thrombophilic factors were measured in an accepted manner. Conference
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Search strategy
A systematic search of publications listed in the electronic databases as MEDLINE, EMBASE and The Cochrane library, from 2008 until October 2014 was conducted, with the limits set to only articles in English language. The following key words were used in combination both as MeSH terms and text words: "thromboembolism or deep vein thrombosis or pulmonary embolism or venous thrombosis or anticoagulation or antithrombotic therapy" and "thrombophilia" or "hypercoagulat*" or "protein C" or "antithrombin" or "protein S" or "(factor 5 leiden or factor v leiden or fv leiden)" or (factor 2 mutation or factor II mutation or prothrombin mutation)" and "adolescen* or child* or infan* or newborn* or neonat* or school child* or baby or babies or toddler* or prematur* or preterm* or vlbw or elbw". Citations of the searched articles were included in the review if they were determined to be relevant. Data extraction was performed in duplicate by two authors (I.L.M.K. and C.H.O).
Quality assessment
Quality assessment of case-control and cohort studies was performed using the
Newcastle-Ottawa Scale (NOS).(7)
Results
A total of 1014 citations were evaluated. Thirteen studies were enrolled in this review, including three case-control studies and 10 cohort studies. 
Venous thrombosis and thrombophilia in neonates
Although the meta-analysis of Young et al showed that thrombophilia contributes to the development of neonatal VTE, it should be realized that neonates were underrepresented in this meta-analysis. In conclusion, only few studies investigated the prevalence and contributing role of thrombophilia in neonatal thrombosis. Neonatal VTE is a multifactorial disease and clinical risk factors seem to play a more important role than inherited thrombophilia, especially in catheter-related VTE.
Thrombophilia in children
The meta-analysis by Young et The most important risk factor in children is a CVC. However, other clinical risk factors, such as malignancy, cardiac disease and nephrotic syndrome, contribute to thrombotic risk as well. (2) The presumed impact of inherited thrombophilia on the thrombotic risk of CVCrelated VTE in children is challenged by results from two recent studies. Albisetti studied thrombotic events in children with malignancies and a port-a-cath by magnetic resonance venography. Only two of 45 (4%) patients with CVC-related VTE had inherited thrombophilia compared to 8 of 69 (12%) patients without VTE. (20) In addition, in the KIDs with Catheter Associated Thrombosis (KIDCAT) study, that included 90 children with heart disease requiring CVCs in the upper venous system for perioperative care, none of the thrombophilic factors showed a significant association with CVC-related VTE. (21) VTE is one of the most serious complications in children with nephrotic syndrome, which is attributed to a net shift in the hemostatic balance toward a hypercoagulable state by selective loss of hemostatic proteins, most notably PS and AT. 20 The reported incidence of VTE in children with nephrotic syndrome varies 
Value of thrombophilia testing
In general, thrombophilia testing should only be performed if the results would change management. As discussed in the previous paragraphs, thrombophilia contributes to VTE in neonates and children, but its extent depends on the specific patient group. Although thrombophilia testing is often performed to gain insight into the cause of VTE in a child, identification of thrombophilia should not be considered the sole cause. Almost all children have one or more clinical risk factors, and unprovoked thrombosis occurs in only 5% of the children. If testing is considered, it seems rational to postpone testing asymptomatic children until they are old enough to decide for themselves after weighing the pros and cons, as the absolute incidence of VTE is very low in children with thrombophilia.(33) Furthermore, diagnosing a true deficiency of AT, PC and PS can be challenging in young children, because of the rapidly developing haemostatic system in the first year of life, and the presence of physiological significant lower levels of certain coagulation inhibiters compared to adults until adolescence. (34) Conclusion VTE in childhood is a multifactorial disease, in which underlying clinical risk factors and inherited thrombophilia contribute to the development of VTE.
The presence of a thrombophilia does not change patients' treatment strategies and consequently testing is not advised routinely in all children with VTE, except for study purposes. However, asymptomatic adult relatives in families with high-risk thrombophilia may benefit from testing by offering them primary thromboprophylaxis in high-risk situations and by counselling the female carriers before the use of oral contraceptives and pregnancy, although it should be realized that negative testing may provide false reassurance. Unprovoked thrombosis and a positive family history may help to predict the presence of thrombophilia in children with VTE. As the incidence of VTE is very low in children with thrombophilia, it seems reasonable to postpone testing in asymptomatic children until they are old enough to decide for themselves in view of the pros and cons. Pre-and post-test counselling should be performed by an experienced haematologist or coagulation specialist. 
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